Abstract
In this work, we designed new terpenoid-peptide conjugates to target the epidermal growth factor receptor (EGFR) and its double mutant EGFR T790M/L858R which are implicated in many cancers. The peptides utilized were MEGPSKCCFSLALSH (MFSL), a new peptide sequence designed by mutating an ErbB2 targeting peptide, while the sequence VPWXE was derived from a peptide motif known to target tumor cells. Each of the peptides were conjugated to four terpenoids, 23-hydroxy betulinic acid (HB), oleanolic acid, perillic acid, and ursolic acid. Molecular docking and molecular dynamics (MD) simulations with the kinase domain of both the wild type and double mutant EGFR receptors revealed that the conjugates formed H-bonds and hydrophobic interactions with key residues in the hinge region, A-loop, and DFG motif, while in the case of the double mutant, interactions also occurred with C-terminal residues and with allosteric sites. MMGBSA analysis revealed higher binding energies for the double mutant. Six of the conjugates were synthesized and self-assembled into nanoassemblies and their impact on tumor cells expressing the wild type and double mutant receptor revealed that higher apoptosis was induced by MFSL conjugates, particularly in cells expressing the double mutant EGFR receptor. The HB and ursolate conjugates were found to be more potent against the tumor cell lines. Overall, these results indicate that these peptides and peptide conjugates can effectively bind to both the wild type and the T790M/L858R receptors to target tumor cells. Such peptide conjugates may be further potentially developed as therapeutic agents for further laboratory studies against tumors overexpressing EGFR.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Associated data are included in the supplementary information. The manuscript will be shared on faculty website.
Code Availability
NA.
References
Agarwal SM, Nandekar P, Saini R (2022) Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, Machine Learning, molecular docking and a dynamics approach. RSC Adv 12(26):16779–16789. https://doi.org/10.1039/d2ra00373b
Ahmadpour S, Hosseinimehr SJ (2019) Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting. Life Sci 239:116870. https://doi.org/10.1016/j.lfs.2019.116870
Ahmed S, Kaur K (2017) Design, synthesis and validation of an in vitro platform peptide-whole cell screening assay using MTT reagent. J Taibah Univ Sci 11(3):487–496. https://doi.org/10.1016/j.jtusci.2016.10.001
Albuschies J, Vogel V (2013) The role of filopodia in the recognition of nanotopographies. Sci Rep 3:1658. https://doi.org/10.1038/srep01658
Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Krämer S, Beck C, Schwab M, Eisenhut M, Haberkorn U (2006) Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. J Nucl Med 47(6):981–988
Azuaje F (2017) Computational models for predicting drug responses in cancer research. Brief Bioinform 18(5):820–829. https://doi.org/10.1093/bib/bbw065
Bag BG, Paul K (2012) Vesicular and fibrillar gels by self-assembly of nanosized oleanolic acid. Asian J Org Chem 1:150–154. https://doi.org/10.1002/ajoc.201200032
Bag BG, Das S, Hasan SN, Barai AC (2017) Nanoarchitectures by hierarchical self-assembly of ursolic acid: entrapment and release of fluorophores including anticancer drug doxorubicin. RSC Adv 7(29):18136–18143. https://doi.org/10.1039/C7RA02123B
Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, Repasky MP, Zhang LY, Berne BJ, Friesner RA, Gallicchio E, Levy RM (2005) Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 26(16):1752–1780. https://doi.org/10.1002/jcc.20292
Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L (2001) Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11(14):1911–1914. https://doi.org/10.1016/s0960-894x(01)00344-4
Bell RA, Storey KB (2014) Novel detection method for chemiluminescence derived from the Kinase-Glo luminescent kinase assay platform: advantages over traditional microplate luminometers. MethodsX 1:96–101. https://doi.org/10.1016/j.mex.2014.07.003
Bergdorf M, Baxter S, Rendleman CA, Shae DE (2016) Desmond/GPU performance as of November 2016. D.E. Shaw Research Technical Report DESRES/T-2019-01. https://www.deshawresearch.com/publications/Desmond-GPU%20Performance%20as%20of%20November%202016.pdf. Accessed 27 July 2023
Beyett TS, To C, Heppner DE, Rana JK, Schmoker AM, Jang J, Clercq D, Gomez G, Scott D, Gray NS, Janne P, Eck MJ (2022) Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nat Commun 13(1):2530. https://doi.org/10.1038/s41467-022-30258-y
Bose R, Zhang X (2009) ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res 315(4):649–658. https://doi.org/10.1016/j.yexcr.2008.07.031
Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossvary I, Moraes MA, Sacerdoti FD, Salmon JK, Shan Y, Shaw DE (2006) Molecular Dynamics—Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proc ACM/IEEE Conf SC06 84-es. https://doi.org/10.1145/1188455.1188544
Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7(5):R788–R795. https://doi.org/10.1186/bcr1304
Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A (2011) Treatment of non-small cell lung cancer with erlotinib or gefitinib. N Engl J Med 364(10):947–955. https://doi.org/10.1056/NEJMct0807960
Chadalapaka G, Jutooru I, Burghardt R, Safe S (2010) Drugs that target specificity proteins downregulate epidermal growth factor receptors in bladder cancer cells. Mol Cancer Res 8(5):739–750. https://doi.org/10.1158/1541-7786.MCR-09-0493
Chen S, Zhao X, Chen J, Chen J, Kuznetsova L, Wong SS, Ojima I (2010) Mechanism-based tumor-targeting drug delivery system Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconj. Chem 21(5):979–987. https://doi.org/10.1021/bc9005656
Cheng Z, Li M, Dey R, Chen Y (2021) Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 14(1):85. https://doi.org/10.1186/s13045-021-01096-0
Costa SA, Mozhdehi D, Dzuricky MJ, Isaacs FJ, Brustad EM, Chilkoti A (2019) Active targeting of cancer cells by nanobody decorated polypeptide micelle with bio-orthogonally conjugated drug. Nano Lett 19(1):247–254. https://doi.org/10.1021/acs.nanolett.8b03837
Dasmahapatra U, Kumar CK, Das S, Subramanian PT, Murali P, Isaac AE, Ramanathan K, Mm B, Chanda K (2022) In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. Front Chem 10:991369. https://doi.org/10.3389/fchem.2022.991369
Debala DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Mayazewal T (2021) New approaches and procedures for cancer treatment: current perspectives. Sage Open Med 9:20503121211034370. https://doi.org/10.1177/20503121211034366
Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. https://doi.org/10.1186/s12943-018-0782-4
Durrant JD, McCammon JA (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9:71. https://doi.org/10.1186/1741-7007-9-71
Emami L, Khabnadideh S, Faghih Z, Farahvasi F, Zonobi F, Gheshlaghi SZ, Daili S, Ebrahimi A, Faghih Z (2022) Synthesis, biological evaluation, and computational studies of some novel quinazoline derivatives as anticancer agents. BMC Chem 16(1):100. https://doi.org/10.1186/s13065-022-00893-z
Ferdausi N, Islam S, Rimti FH, Quayum ST, Arshad EM, Ibnat A, Islam T, Arefin A, Ema TI, Biswas P, Dey D, Al Azad S (2022) Point-specific interactions of isovitexin with the neighboring amino acid residues of the hACE2 receptor as a targeted therapeutic agent in suppressing the SARS-CoV-2 influx mechanism. J Adv Vet Anim Res 9(2):230–240. https://doi.org/10.5455/javar.2022.i588
Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796–810. https://doi.org/10.1007/s11095-010-0073-2
Fischer M (2010) Amine coupling through EDC/NHS: a practical approach. Methods Mol Biol 627:55–73. https://doi.org/10.1007/978-1-60761-670-2_3
Forouzesh N, Mishra N (2021) An effective MM/GBSA protocol for absolute binding free energy calculations: a case study on SARS-CoV-2 spike protein and the human ACE2 receptor. Molecules 26(8):2383. https://doi.org/10.3390/molecules26082383
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD et al (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95(20):12022–12027. https://doi.org/10.1073/pnas.95.20.12022
Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, Kath JC, Stewart A (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21(2):209–219. https://doi.org/10.1016/j.str.2012.11.014
Gao H, Wang Y, Chen C, Chen J, Wei Y, Cao S, Jiang X (2014) Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 461(1–2):478–488. https://doi.org/10.1016/j.ijpharm.2013.12.016
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449–461. https://doi.org/10.1517/17460441.2015.1032936
Ghandehari F, Behbahani M, Pourazar A, Noormohammadi Z (2015) In silico and in vitro studies of cytotoxic activity of different peptides derived from vesicular stomatitis virus G protein. Iran J Basic Med Sci 18(1):47–52. https://doi.org/10.5812/jkums.69544
Ghasemi M, Turnbull T, Sebastian S, Kempson I (2021) The MTT assay: utility, limitations, pitfalls and interpretation in bulk and single-cell analysis. Int J Mol Sci 22(23):12827. https://doi.org/10.3390/ijms222312827
Ghosh S, Bishayee K, Khuda-Bukhsh AR (2014) Oleanolic acid isolated from ethanolic extract of Phytolacca decandra induces apoptosis in A375 skin melanoma cells: drug-DNA interaction and signaling cascade. J Integr Med 12(2):102–114. https://doi.org/10.1016/S2095-4964(14)60015-7
Gu G, Hu Q, Feng X, Gao X, Menglin J, Kang T, Jiang D, Song Q, Chen H, Chen J (2014) PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Biomaterials 35(28):8215–8226. https://doi.org/10.1016/j.biomaterials.2014.06.022
Gurrapu N, Praveen Kumar E, Kolluri PK, Putta S, Sivan SK, Subhashini NJP (2020) Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole tethered chalcone hybrids as potential anticancer agents. J Mol Struc 1217:128356. https://doi.org/10.1016/j.molstruc.2020.128356
Hein JI, Scholz J, Köber S, Kaufmann T, Faix J (2023) Unleashed actin assembly in capping protein deficient B16–F1 cells enables identification of multiple factors contributing to filopodium formation. Cells 12(6):890. https://doi.org/10.3390/cells12060890
Honegger AM, Dull TJ, Felder S, VanObberghen E, Bellot F, Szapary D, Schmidt A, Schlessinger J (1987) Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51:199–209. https://doi.org/10.1016/0092-8674(87)90147-4
Jagtap JM, Parchur AK, Sharma G (2020) Smart nanomaterials for tumor targeted hyperthermia. In: Ahmad N, Gopinath P (eds) Intelligent nanomaterials for drug delivery applications. Chp. 3, pp 43–59
Ji ZN, Ye WC, Liu GG, Hsiao WL (2002) 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. Life Sci 72(1):1–9. https://doi.org/10.1016/s0024-3205(02)02176-8
Juul-Madsen K, Troldborg A, Wittenborn T, Axelsen M, Zhao H, Klausen L, Luecke S, Paludan S, Stengaard-Pedersen K, Dong M, Moller H, Thiel S, Jensen H, Schuck P, Sutherland D, Degn S, Vorup-Jensen T (2021) Characterization of DNA-protein complexes by nanoparticle tracking analysis and their association with systemic lupus. PNAS 118(30):e2106647118. https://doi.org/10.1073/pnas.2106647118
Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J (2015) A structural perspective on the regulation of the EGF receptor. Annu Rev Biochem 84:739–764. https://doi.org/10.1146/annurev-biochem-060614-034402
Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor. J Clin Oncol 26(10):1742–1751. https://doi.org/10.1200/JCO.2007.12.1178
Kumar BK, Faheem SKVGC, Ojha R, Prajapati VK, Pai A, Murugesan S (2022) Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. J Biomol Struct Dyn 40(3):1363–1386. https://doi.org/10.1080/07391102.2020.1824814
Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV (2019) Targeted delivery to tumors: multidirectional strategies to improve treatment efficiency. Cancers 11(1):68. https://doi.org/10.3390/cancers11010068
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ, Park SY (2015) Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer 112(1):103–111. https://doi.org/10.1038/bjc.2014.556
Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY (2016) Discovery of (R, E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers. J Med Chem 59(14):6671–6689. https://doi.org/10.1021/acs.jmedchem.5b01985
Li J, Guo WJ, Yang QY (2002) Effects of ursolic acid and oleanolic acid on human colon carcinoma cell line HCT15. World J Gastroenterol 8(3):493–495. https://doi.org/10.3748/wjg.v8.i3.493
Li S, Huang S, Peng SB (2005) Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 27(5):1329–1339. https://doi.org/10.3892/ijo.27.5.1329
Liao SM, Du QS, Meng JZ, Pang ZW, Huang RB (2013) The multiple roles of histidine in protein interactions. Chem Cent J 7(1):44. https://doi.org/10.1186/1752-153X-7-44
Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti RM (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 33(5):784–811. https://doi.org/10.1210/er.2012-1014
Liu M, Zhao X, Xiao L, Liu G, Liu H, Wang X, Feng X, Lin X (2015) Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol 53(1):1–9. https://doi.org/10.3109/13880209.2014.907323
Lowder MA, Doerner AE, Schepartz A (2015) Structural differences between wild type and double mutant EGFR modulated by third-generation kinase inhibitors. J Am Chem Soc 137(20):6456–6459. https://doi.org/10.1021/jacs.5b02326
Lu L, Zhang H, Liu J, Liu Y, Wang Y, Xu S, Zhu Z, Xu J (2019) Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents. Eur J Med Chem 182:111659. https://doi.org/10.1016/j.ejmech.2019.111659
Luo Z, Akerman B, Zhang S, Norden B (2010) Structures of self-assembled amphiphilic peptide-heterodimers: effects of concentration, pH, temperature and ionic strength. Soft Matter 6:2260–2270. https://doi.org/10.1039/B926962B
Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I, Hussain AF (2019) Molecular targeting therapy against EGFR family in breast cancer: Progress and future potentials. Cancers 11(12):1826. https://doi.org/10.3390/cancers11121826
Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL (2019) Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer. Cells 8(4):316. https://doi.org/10.3390/cells8040316
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331–345. https://doi.org/10.1007/s10549-012-2289-9
McKinnon KM (2018) Flow cytometry: an overview. Curr Protoc Immunol 120:5.1.1-5.1.11. https://doi.org/10.1002/cpim.40
Mehmankhah M, Ramachandran S, Alam MA (2014) Predicting probable ligands to inhibit HER2-EGFR in gastric cancer. IOSR J Pharm Biol Sci 9(3):37–49. https://doi.org/10.9790/3008-09363749
Minashi K, Yamada T, Hosaka H, Amagai K, Shimizu Y, Kiyozaki H, Sato M, Soeda A, Endo S, Ishida H, Kamoshida T, Sakai Y, Shitara K (2021) Cancer related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. Jpn J Clin Oncol 51(10):1523–1533. https://doi.org/10.1093/jjco/hyab104
Minnelli C, Laudadio E, Mobbili G, Galeazzi R (2020) Conformational insight on WT- and mutated EGFR receptor activation and inhibition by epigallocatechin-3-gallate: over a rational basis for the design of selective non-small cell lung cancer anticancer agents. Int J Mol Sci 21(5):1721. https://doi.org/10.3390/ijms21051721
Mirza Z, Schulten HJ, Farsi H, Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH, Karim S (2015) Molecular interaction of a kinase inhibitor Midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics. PLoS ONE 10(3):e0119765. https://doi.org/10.1371/journal.pone.0119765
Morency LP, Gaudreault F, Najmanovich R (2018) Applications of the NRGsuite and the molecular docking software FlexAID in computational drug discovery and design. Methods Mol Biol 1762:367–388. https://doi.org/10.1007/978-1-4939-7756-7_18
Mukund V, Saddala MS, Farran B, Mannavarapu M, Alam A, Nagaraju GP (2019) Molecular docking studies of angiogenesis target protein HIF-1α and genistein in breast cancer. Gene 701:169–172. https://doi.org/10.1016/j.gene.2019.03.062
Mulyadi M (2011) Cytotoxicity test pentacyclic triterpenes of Eupatorium inulifolium HBK on myeloma cells and their docking study. Indonesian J Pharm 22(3):182–190
Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281–289. https://doi.org/10.3816/CLC.2009.n.039
Ovesná Z, Kozics K, Slamenová D (2006) Protective effects of ursolic acid and oleanolic acid in leukemic cells. Mutat Res 600(1–2):131–137. https://doi.org/10.1016/j.mrfmmm.2006.03.008
Palanivel S, Yli-Harja O, Kandhavelu M (2022) Molecular interaction study of novel indoline derivatives of EGFR-kinase domain using multiple computational analysis. J Biomol Struc Dyn 40(16):7545–7554. https://doi.org/10.1080/07391102.2021.1900917
Peng YH, Shiao HY, Tu CH, Liu PM, Hsu JT, Amancha PK, Wu JS, Coumar MS, Chen CH, Wang SY, Lin WH, Sun HY, Chao YS, Lyu PC, Hsieh HP, Wu SY (2013) Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. J Med Chem 56(10):3889–3903. https://doi.org/10.1021/jm400072p
Purba ER, Saita EI, Maruyama IN (2017) Activation of the EGF receptor by ligand binding and oncogenic mutations: the “Rotation Model.” Cells 6(2):13. https://doi.org/10.3390/cells6020013
Ramirez D, Caballero J (2018) Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data. Molecules 23(5):1038. https://doi.org/10.3390/molecules23051038
Rashid H, Ahmad N, Abdalla M, Khan K, Utera Martines MA, Shabana S (2022) Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodenside A against pathogenic proteins of SARS-CoV-2. J Mol Struct 1247:131296. https://doi.org/10.1016/j.molstruc.2021.131296
Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR (2011) Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp 50:2597. https://doi.org/10.3791/2597
Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116(5):1234–1242. https://doi.org/10.1002/cncr.24816
Roskoski RJ (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26–48. https://doi.org/10.1016/j.phrs.2015.10.021
Salentin S, Haupt VJ, Daminelli S, Schroeder M (2014) Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity assessment. Prog Biophys Mol Biol 116(2–3):174–186. https://doi.org/10.1016/j.pbiomolbio.2014.05.006
Shan JZ, Xuan YY, Zheng S, Dong Q, Zhang SZ (2009) Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J Zhejiang Univ Sci B 10(9):668–674. https://doi.org/10.1631/jzus.B0920149
Sheikh IA, Hassan HM (2016) In silico identification of novel erlotinib analogues against epidermal growth factor receptor. Anticancer Res 36(11):6125–6132. https://doi.org/10.21873/anticanres.11203
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer 2(12):1097–1105. https://doi.org/10.1177/1947601911423031
Suenaga A, Okimoto N, Hirano Y, Fukui K (2012) An efficient computational method for calculating ligand binding affinities. PLoS ONE 7(8):e42846. https://doi.org/10.1371/journal.pone.0042846
Tamirat MZ, Koivu M, Elenius K, Johnson MS (2019) Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. PLoS ONE 14(9):e0222814. https://doi.org/10.1371/journal.pone.0222814
Tang Z, Du R, Jiang S, Wu C, Barkauskas DS et al (2008) Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99(6):911–922. https://doi.org/10.1038/sj.bjc.6604559
Tang ZY, Li Y, Tang YT, Ma XD, Tang ZY (2022) Anticancer activity of oleanolic acid and its derivatives: recent advances in evidence, target profiling and mechanisms of action. Biomed Pharmacother 145:112397. https://doi.org/10.1016/j.biopha.2021.112397
Tarasov SG, Gaponenko V, Howard OM, Chen Y, Oppenheim JJ, Dyba MA, Subramaniam S, Lee Y, Michejda C, Tarasova NI (2011) Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles. Proc Natl Acad Sci USA 108(24):9798–9803. https://doi.org/10.1073/pnas.1014598108
Trott O, Olson AJ (2012) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334
Vijayakumar S, Lakshmi PTV (2015) ACPP: a web server for prediction and design of anti-cancer peptides. Int J Pept Res Ther 21(1):99–106. https://doi.org/10.1007/s10989-014-9435-7
Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M (2008) Somatostatin, cortistatin and their receptors in tumors. Mol Cell Endocrinol 286(1–2):219–229. https://doi.org/10.1016/j.mce.2007.12.002
Wang YK, Gao CF, Yun T, Chen Z, Zhang XW, Lv XX, Meng NL, Zhao WZ (2011) Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet 4(1):14. https://doi.org/10.1186/1755-8166-4-14
Worm DJ, Els-Heindl S, Beck-Sickinger AG (2020) Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates. Pept Sci 112(3):24171. https://doi.org/10.1002/pep2.24171
Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ (2009) Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol 95(3):355–365. https://doi.org/10.1007/s11060-009-9945-x
Yang K, Chen Y, Zhou J, Ma L, Shan Y, Cheng X, Wang Y, Zhang Z, Ji X, Chen L, Dai H, Zhu B, Li C, Tao Z, Hu X, Yin W (2019) Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small–cell lung carcinoma harboring EGFR T790M mutations. Br J Pharmacol 176(24):4609–4624. https://doi.org/10.1111/bph.14793
Yeruva L, Pierre KJ, Elegbede A, Wang RC, Carper SW (2007) Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 257(2):216–226. https://doi.org/10.1016/j.canlet.2007.07.020
Yin R, Li T, Tian JX, Xi P, Liu RH (2017) Ursolic acid, a potential anticancer compound for breast cancer therapy. Crit Rev Food Sci Nutr 58(4):568–574. https://doi.org/10.1080/10408398.2016.1203755
Yu J, Zhou Y, Tanaka I, Yao M (2010) Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere. Bioinformatics 26(1):46–52. https://doi.org/10.1093/bioinformatics/btp599
Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25(2):423–428. https://doi.org/10.1093/annonc/mdt573
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137–1149. https://doi.org/10.1016/j.cell.2006.05.013
Zhang XY, Zhang YK, Wang YJ, Gupta P, Zeng L, Xu M, Wang XQ, Yang DH, Chen ZS (2016) Osimertinib (AZD9291), a mutant selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Molecules 21(9):1236. https://doi.org/10.3390/molecules21091236
Zhang X, Sanchez-Perez H, Lightsone FC (2017) A comprehensive docking and MM/GBSA rescoring study of ligand recognition upon binding antithrombin. Curr Top Med Chem 17(14):1631–1639
Zhao P, Yao MY, Zhu SJ, Chen JY, Yun CH (2018) Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045. Biochem Biophys Res Commun 502(3):332–337. https://doi.org/10.1016/j.bbrc.2018.05.154
Zhao Z, Xie L, Bourne PE (2020) Structural insights into characterizing binding sites in EGFR kinase mutants. J Chem Inf Model 59(1):453–462. https://doi.org/10.1021/acs.jcim.8b00458
Zhu SJ, Zhao P, Yang J, Ma R, Yan XE, Yang SY, Yang JW, Yun CH (2018) Structural insights into drug development strategy targeting EGFR T90M/C797S. Oncotarget 9(17):13652–13665. https://doi.org/10.18632/oncotarget.24113
Acknowledgements
All authors thank the Advanced Research Computing, Education Technologies and Research Computing department at Fordham University, a division of the Office of Information Technology for providing their assistance and access to research computing resources that have contributed to the results reported here. IB also thanks the Keck Biotechnology Laboratory for help with NTA experiments.
Funding
IB thanks NSF-MRI grant # 1626378 and NSF-MRI grant # 2117625 for the acquisition of the AFM and the FACS instruments respectively. IB also thanks the research office at Fordham University for financial support. BG and HH thank the Henry Luce Foundation for the Clare Boothe Luce Scholarship for financial support of this work. IB thanks the Fordham University research office for financial support.
Author information
Authors and Affiliations
Contributions
MR and BG—In silico modeling, interpretation of data, data curation, in vitro studies, data analysis and writing parts of the manuscript; HH: In vitro studies including viability and FACS assays and writing and editing parts of the manuscript. IB: Conceptualization, supervision, experimental design, data analysis, editing and writing the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Ethics Approval and Consent to Participate
N/A.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rico, M.I., Goncalves, B.G., Hunt, H.L. et al. Design and Self Assembly of Tri-Terpene Peptide Conjugates and Their Interactions with EGFR and EGFR Mutant Receptors: An In Silico and In Vitro Study. Int J Pept Res Ther 30, 3 (2024). https://doi.org/10.1007/s10989-023-10583-6
Accepted:
Published:
DOI: https://doi.org/10.1007/s10989-023-10583-6